patients with metastatic melanoma treated with tremelimumab (CTLA-4-targeted MAb), either alone or in combination with other types of immunotherapy, demonstrated increased numbers of circulating Th17 cells, measured as IL-17A-secreting CD4+ T cells following activation in vitro (109). The gene discussed is IL17A; the disease is metastatic melanoma.